FIELD: organic chemistry, natural compounds, pharmacy.
SUBSTANCE: method involves mixing ergot derivative or its mixture with pharmaceutically acceptable hydrophilic swelling substance or its mixture and with one or some pharmaceutically acceptable vehicles. Derivative of ergot has the following formula: wherein R1 means hydrogen or halogen atom; R2 means hydrogen atom or (C1-C4)-alkyl; R3 represents isopropyl, sec.-butyl, isobutyl or benzyl; R4 represents methyl, ethyl or isopropyl; R5 means hydrogen atom; R6 means hydrogen atom or methoxy-group, or R5 and R6 in common correspond to the additional bond. The ratio of ergot derivative to swelling agent = (1-0.5):(1-10). Pharmaceutical composition containing the substance prepared by above indicated method comprises from 5 to 80 mg of ergot derivative in its ratio to swelling agent from 1:0.5 to 1:10. Invention provides realization the indicated designation.
EFFECT: improved methods for preparing, valuable properties of compositions.
6 cl, 6 tbl, 1 dwg, 8 ex
Title | Year | Author | Number |
---|---|---|---|
LAMOTRIGINE-BASED COMPOSITIONS OF PROLONGED RELEASE | 2003 |
|
RU2325163C2 |
PHARMACEUTICAL COMPOSITION CONTAINING BIOTIN AND METHOD FOR ITS PRODUCTION | 2017 |
|
RU2639488C1 |
PHARMACEUTICAL COMPOSITION OF PROLONGED ACTION BASED ON CLOZAPINE OF PERORAL INTRODUCTION | 2009 |
|
RU2414903C1 |
CONTROLLED-RELEASE PHARMACEUTICAL PROXODOLOL COMPOSITION | 2007 |
|
RU2356532C2 |
PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION OF ENTACAPONE OR ITS SALTS | 2009 |
|
RU2540465C2 |
TABLETS OF TAMSULOSIN WITH MODIFIED RELEASE | 2002 |
|
RU2335280C2 |
TACROLIMUS FOR IMPROVED TREATMENT OF PATIENTS WITH GRAFTS | 2009 |
|
RU2574006C2 |
PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN | 2008 |
|
RU2484816C2 |
PHARMACOLOGICAL COMPOSITION WITH SWELLING COATING | 2004 |
|
RU2375048C2 |
THE PHARMACEUTICAL COMPOSITIONS CONTAINING pH - DEPENDENT MEDICAL PRODUCT, THE pH MODIFIER AND THE SLOWING DOWN AGENT | 2006 |
|
RU2442574C2 |
Authors
Dates
2005-07-20—Published
2000-11-30—Filed